Absci (ABSI) vs ICON (ICLR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Absci (ABSI) has outperformed ICON (ICLR) over the past year, gaining 146.5% versus a loss of 12.1%. Over five years, ABSI leads with a -13.3% price change compared with -40.3% for ICLR. ICON is the larger company by market cap ($12.42 billion vs $1.54 billion), about 8.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | ICLR |
|---|---|---|
| Share price | $8.98 | $161.00 |
| Market cap | $1.54B | $12.42B |
| 1-day change | -2.66% | -1.88% |
| YTD return | +164.18% | -9.95% |
| 1-year return | +146.52% | -12.09% |
| 5-year return | -13.26% | -40.34% |
| P/E ratio (TTM) | — | 169.47 |
| Forward P/E | — | 13.62 |
| EPS (TTM) | $-0.79 | $0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $8.25B |
| Revenue growth (YoY) | — | +0.76% |
| Net income (latest FY) | — | $229.34M |
| Gross margin | — | 26.37% |
| Operating margin | — | 5.37% |
| Net margin | — | 2.78% |
| 52-week high | $12.06 | $203.91 |
| 52-week low | $2.24 | $66.57 |
| Distance from 52-week high | -25.55% | -21.05% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +60.45% | +14.54% |
| Average volume | 3.45M | 814.74K |
| Shares outstanding | 171.61M | 77.15M |
| Employees | 140 | 40,200 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICON is about 8.1 times larger than Absci by market value ($12.42B vs $1.54B).
- ABSI has outperformed ICLR by 158.6 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About ICON
ICLR stock →ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 40,200 employees
ABSI vs ICLR FAQ
Which is bigger, Absci or ICON?
ICON (ICLR) is larger, with a market capitalization of $12.42B compared with $1.54B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or ICLR?
ABSI returned +146.52% over the past 12 months, compared with -12.09% for ICLR (price return, excluding dividends). Past performance does not predict future results.
Are Absci and ICON in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.